ESMO2019 confress 演題レポート Barcelona, Spain 27 Sep - 01 Oct 2019

2019年9月27日~10月1日にスペイン・バルセロナで開催された 2019年 欧州臨床腫瘍学会学術集会(ESMO 2019 Congress)より、大腸癌や胃癌などの消化器癌の注目演題のレポートをお届けします。演題レポートの冒頭には、臨床研究の第一線で活躍する監修ドクターのコメントを掲載します。

Live Short Cuts

演題レポート

Proffered Paper Session

#LBA10
胆道癌

ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib vs placebo in patients with advanced cholangiocarcinoma with an isocitrate dehydrogenase 1 (IDH1) mutation

Ghassan K. Abou-Alfa, et al.

#LBA30
大腸癌

Analysis of circulating tumor DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: prognostic and predictive value for adjuvant treatment duration

Julien Taieb, et al.

#LBA32
大腸癌

Encorafenib plus Cetuximab With or Without Binimetinib for BRAF V600E-Mutant Metastatic Colorectal Cancer: Expand Results from a Randomized, 3-Arm, Phase 3 Study vs. the Choice of Either Irinotecan or FOLFIRI plus Cetuximab (BEACON CRC)

Josep Tabernero, et al.

#LBA38
肝細胞癌

CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab vs Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma

Thomas Yau, et al.

#LBA41
胃癌

A Phase III open label randomized study of neoadjuvant chemotherapy with docetaxel, oxaliplatin and S-1 (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1 for resectable advanced gastric cancer (PRODIGY Study)

Yoon-Koo Kang, et al.

#LBA43
胃癌

Randomized phase 3 ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens

Yoon-Koo Kang, et al.

#LBA44
胃癌

Pembrolizumab With or Without Chemotherapy vs Chemotherapy in Patients With Advanced G/GEJ Cancer Including Outcomes According to Microsatellite Instability-High Status in KEYNOTE-062

Kohei Shitara, et al.

Poster Discussion Session

#526PD
大腸癌

TRIUMPH: Primary Efficacy of a Phase II Trial of Trastuzumab (T) and Pertuzumab (P) in Patients (pts) with Metastatic Colorectal Cancer (mCRC) with HER2 (ERBB2) Amplification (amp) in Tumor Tissue or Circulating Tumor DNA (ctDNA): A GOZILA Sub-study

Yoshiaki Nakamura, et al.

#533PD
大腸癌

BACCI: A Phase II Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Capecitabine Bevacizumab plus Atezolizumab or Placebo in Refractory Metastatic Colorectal Cancer: An ACCRU Network Study

Niharika B. Mettu, et al.

#674PD
胃癌

Perioperative FLOT + anti-PD-L1 Avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma: safety and biomarker data from the ICONIC trial safety run-in

Michael Davidson, et al.

Poster Display Session

#571P
大腸癌

Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study (C3)

Takeshi Nagasaka, et al.

#790P
胃癌

A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604)

Daisuke Takahari, et al.

#820P
胃癌

Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)

Yu Sunakawa, et al.

by European Society for Medical Oncology